{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:54:59Z","timestamp":1760100899776,"version":"3.37.3"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Iron chelation in the transfusion-dependent anaemias management is essential to prevent end-organ damage and to improve survival. Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity. Therapeutic drug monitoring is an important tool for optimizing drug utilization and doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A fully validated chromatographic method was used to quantify deferasirox concentration in plasma collected from paediatric patients with \u03b2-thalassaemia. Samples obtained after 5 days of washout or in na\u00efve patients before and after 2, 4, 6 and 24 h drug administration were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Associations between variables were tested using the Pearson test. Twenty paediatric patients were enrolled; they were mainly men (13.65%), with median age of 6.35 years and body mass index of 15.45 kg\/m2. Concerning pharmacokinetic parameters, a higher interindividual variability was shown. A positive, but not significant, correlation (r = 0.363; P = 0.115) was found between deferasirox area under the concentration curve over 24 h (AUC) and drug dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Monitoring plasma deferasirox concentrations appears beneficial for guiding appropriate patient treatment, enhancing effectiveness and minimizing toxicity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12559","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T10:28:49Z","timestamp":1464344929000},"page":"525-528","source":"Crossref","is-referenced-by-count":5,"title":["Deferasirox pharmacokinetic evaluation in \u03b2-thalassaemia paediatric patients"],"prefix":"10.1093","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4933-0011","authenticated-orcid":false,"given":"Sarah","family":"Allegra","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"De Francia","sequence":"additional","affiliation":[{"name":"Department of Biological and Clinical Sciences, University of Turin , Orbassano, Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Pirro","sequence":"additional","affiliation":[{"name":"Department of Biological and Clinical Sciences, University of Turin , Orbassano, Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Massano","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Centre for Microcitemie, S. Luigi Gonzaga Hospital, University of Turin , Orbassano, Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Piga","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Centre for Microcitemie, S. Luigi Gonzaga Hospital, University of Turin , Orbassano, Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"D'Avolio","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin , Turin,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,1]]},"reference":[{"key":"2024103012562488500_jphp12559-cit-0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2007-08-109306","article-title":"Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major","volume":"111","author":"Cohen","year":"2008","journal-title":"Blood"},{"key":"2024103012562488500_jphp12559-cit-0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1172-5-11","article-title":"Beta-thalassemia","volume":"5","author":"Galanello","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2024103012562488500_jphp12559-cit-0003","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1124\/dmd.109.030833","article-title":"Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state","volume":"38","author":"Waldmeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"2024103012562488500_jphp12559-cit-0004","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1124\/dmd.108.022962","article-title":"Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats","volume":"36","author":"Bruin","year":"2008","journal-title":"Drug Metab Dispos"},{"volume-title":"Exjade (Deferasirox) Tablets for Oral Suspension [Prescribing Information]","year":"2006","author":"Novartis","key":"2024103012562488500_jphp12559-cit-0005"},{"key":"2024103012562488500_jphp12559-cit-0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/17512433.1.2.231","article-title":"Once-daily oral deferasirox for the treatment of transfusional iron overload","volume":"1","author":"Galanello","year":"2008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2024103012562488500_jphp12559-cit-0007","first-page":"565","article-title":"Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia","volume":"43","author":"Galanello","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2024103012562488500_jphp12559-cit-0008","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2009-05-222729","article-title":"Deferasirox pharmacokinetics in patients with adequate versus inadequate response","volume":"114","author":"Chirnomas","year":"2009","journal-title":"Blood"},{"key":"2024103012562488500_jphp12559-cit-0009","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"key":"2024103012562488500_jphp12559-cit-0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jbmr.522","article-title":"A case of hypophosphatemic osteomalacia secondary to deferasirox therapy","volume":"27","author":"Milat","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2024103012562488500_jphp12559-cit-0011","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"2024103012562488500_jphp12559-cit-0012","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2014.65","article-title":"Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness","volume":"15","author":"Cusato","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"2024103012562488500_jphp12559-cit-0013","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2012.02.047","article-title":"A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients","volume":"893\u2013894","author":"De Francia","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2024103012562488500_jphp12559-cit-0014","first-page":"1343","article-title":"Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major","volume":"91","author":"Galanello","year":"2006","journal-title":"Haematologica"},{"key":"2024103012562488500_jphp12559-cit-0015","first-page":"873","article-title":"Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload","volume":"91","author":"Piga","year":"2006","journal-title":"Haematologica"},{"key":"2024103012562488500_jphp12559-cit-0016","doi-asserted-by":"crossref","first-page":"e64114","DOI":"10.1371\/journal.pone.0064114","article-title":"Pharmacogenetic study of deferasirox, an iron chelating agent","volume":"8","author":"Lee","year":"2013","journal-title":"PLoS One"},{"key":"2024103012562488500_jphp12559-cit-0017","doi-asserted-by":"crossref","DOI":"10.2217\/pgs-2015-0001","article-title":"Role of pharmacogenetics on deferasirox AUC and efficacy","volume-title":"Pharmacogenomics","author":"Cusato","year":"2016"},{"key":"2024103012562488500_jphp12559-cit-0018","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/tpj.2014.65","article-title":"Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness","volume":"15","author":"Cusato","year":"2015","journal-title":"Pharmacogenomics J"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12559","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/5\/525\/60231111\/jphp12559.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/69\/5\/525\/60231111\/jphp12559.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:26:20Z","timestamp":1730312780000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/69\/5\/525\/6128972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,1]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,1]]},"published-print":{"date-parts":[[2017,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12559","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2017,5]]},"published":{"date-parts":[[2017,5,1]]}}}